TEASE Studies

The TEASE trials consist of four clinical studies of gildeuretinol acetate (ALK-001) in Stargardt disease, denoted as TEASE-1, TEASE-2, TEASE-3 and TEASE-4.

• The TEASE-1 study was a randomized, double-masked, placebo-controlled trial in 50 patients with advanced Stargardt disease. (Completed)
• The TEASE-2 trial was a randomized, double-masked, placebo-controlled trial in 80 patients with moderate Stargardt disease. (Completed)
• TEASE-3 (NCT02402660), an ongoing clinical trial in early-stage Stargardt disease, is an open-label study of gildeuretinol in genetically confirmed patients with early signs of disease visible on retinal imaging, but who have not begun experiencing symptoms of vision loss.
• TEASE-4 (NCT04239625) is an open-label extension study.